<DOC>
	<DOCNO>NCT02525094</DOCNO>
	<brief_summary>To assess efficacy safety MEDI9929 adult subject Atopic Dermatitis</brief_summary>
	<brief_title>Phase 2a Study Evaluate Efficacy Safety MEDI9929 Adults With Atopic Dermatitis</brief_title>
	<detailed_description>This Phase 2a , randomize , double-blinded , placebo-controlled study evaluate efficacy safety MEDI9929 administer subcutaneously adult subject moderate severe Atopic Dermatitis . Subjects randomize 1:1 fashion stratify screen . Approximately 100 subject plan randomize approximately 35 site 6 country</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>AD meeting Hanifin Rajka criterion Age 1875 year inclusive screen Atopic dermatitis affect great than/equal 10 % body surface area Moderate severe AD Effective birth control line protocol detail Active dermatologic condition may confuse diagnosis Atopic Dermatitis Hepatitis B , C HIV Pregnant breastfeed History anaphylaxis follow biologic therapy History clinically significant infection within 4 week prior Visit 3 Diagnosis helminth parasitic infection within 6 month screen History Cancer except basal cell Receipt market investigational biologic agent within 4 month visit 3 Any clinically relevant abnormal find Major surgery within 8 week prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Eczema</keyword>
</DOC>